Alnylam Pharmaceuticals (ALNY) Non-Current Debt (2016 - 2022)
Alnylam Pharmaceuticals' (ALNY) quarterly Non-Current Debt came in at $677.7 million in Q2 2022, up 56.46% YoY from $433.2 million in Q2 2021, and little changed on a QoQ basis from $676.7 million in Q1 2022.
Alnylam Pharmaceuticals (ALNY) Non-Current Debt (2016 - 2022) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 7 years of Non-Current Debt data on file, last reported at $677.7 million in Q2 2022.
- Quarterly Non-Current Debt rose 56.46% year-over-year to $677.7 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $677.7 million (up 56.46% YoY) and the FY2021 annual result came in at $675.7 million, up 253.25% from the prior year.
- Non-Current Debt was little changed at $677.7 million in Q2 2022, from $676.7 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $677.7 million in Q2 2022 to a low of $30.0 million in Q1 2018.
- A 5-year average of $266.1 million and a median of $191.3 million in 2020 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2018 — Non-Current Debt slumped 80.0% — and 2021, when it surged 253.25%.
- Tracing ALNY's Non-Current Debt over 5 years: stood at $30.0 million in 2018, then changed by 0.0% to $30.0 million in 2019, then jumped by 537.59% to $191.3 million in 2020, then surged by 253.25% to $675.7 million in 2021, then increased by 0.3% to $677.7 million in 2022.
- The last three Non-Current Debt figures came in at $677.7 million (Q2 2022), $676.7 million (Q1 2022), and $675.7 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 677.72 Mn |
| Mar 31, 2022 | 676.71 Mn |
| Dec 31, 2021 | 675.70 Mn |
| Sep 30, 2021 | 433.80 Mn |
| Jun 30, 2021 | 433.15 Mn |
| Mar 31, 2021 | 191.59 Mn |
| Dec 31, 2020 | 191.28 Mn |
| Jun 30, 2019 | 30.00 Mn |
| Mar 31, 2019 | 30.00 Mn |
| Dec 31, 2018 | 30.00 Mn |
| Sep 30, 2018 | 30.00 Mn |
| Jun 30, 2018 | 30.00 Mn |
| Mar 31, 2018 | 30.00 Mn |
| Dec 31, 2017 | 30.00 Mn |
| Sep 30, 2017 | 150.00 Mn |
| Jun 30, 2017 | 150.00 Mn |
| Mar 31, 2017 | 150.00 Mn |
| Dec 31, 2016 | 150.00 Mn |
| Sep 30, 2016 | 150.00 Mn |
| Jun 30, 2016 | 150.00 Mn |